Monopar Therapeutics (MNPR) EBITDA (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of EBITDA data on file, last reported at -$4.1 million in Q3 2025.

• For the quarter ending Q3 2025, EBITDA fell 159.89% year-over-year to -$4.1 million; the trailing twelve-month figure through Sep 2025 stood at -$12.1 million (down 69.49% YoY), and the FY2025 full-year result was $8.5 million, up 258.12% from the prior year.
• EBITDA retreated to -$4.1 million in Q3 2025, from -$3.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.6 million in Q3 2024 to a low of -$4.1 million in Q3 2025.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 31.75% in 2024 and slumped 159.89% in 2025, its largest moves.
• Tracing MNPR's EBITDA over 5 years: stood at -$2.7 million in 2021, then slipped by 8.5% to -$2.9 million in 2022, then gained by 28.98% to -$2.1 million in 2023, then gained by 23.77% to -$1.6 million in 2024, then tumbled by 159.89% to -$4.1 million in 2025.
• Business Quant data shows MNPR's EBITDA at -$4.1 million in Q3 2025, -$3.2 million in Q2 2025, and -$3.2 million in Q1 2025.